ABVC BioPharma
ABVC
11 hedge funds and large institutions have $571K invested in ABVC BioPharma in 2022 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 1 closing their positions.
600% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 1
120% more funds holding
Funds holding: 5 → 11 (+6)
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
15% more capital invested
Capital invested by funds: $498K → $571K (+$72.8K)
0.28% less ownership
Funds ownership: 0.48% → 0.2% (-0.28%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$75.4K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$23.8K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$15.5K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$10.6K |
| 5 |
Jane Street
New York
|
+$9.56K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$1.16K |
| 2 |
BlackRock
New York
|
-$311 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Vanguard Group
Malvern,
Pennsylvania
| $330K | – | – | – |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $122K | +$75.4K | +8,973 | +180% |
|
|
3
BlackRock
New York
| $34K | -$311 | -37 | -0.9% |
|
|
4
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $25K | +$23.8K | +2,829 | New |
|
|
5
Northern Trust
Chicago,
Illinois
| $16K | +$15.5K | +1,842 | New |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $13K | +$7.65K | +910 | +152% |
|
|
7
Citadel Advisors
Miami,
Florida
| $11K | +$10.6K | +1,261 | New |
|
8
Millennium Management
New York
| $10K | +$9.26K | +1,101 | New |
|
|
9
Jane Street
New York
| $10K | +$9.56K | +1,137 | New |
|
|
AC
10
Armistice Capital
New York
| – | -$1.16K | -109,275 | Closed |
|
11
Wells Fargo
San Francisco,
California
| – | +$101 | +12 | New |
|
12
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$202 | +24 | New |
|
ABVC Hedge Fund Activity: Q3 2022 in Review
11 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in ABVC BioPharma (ABVC) for Q3 2022, worth a combined $571K — up 15% from $498K a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new ABVC positions and 1 closed out — a net gain of 6 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Geode Capital Management, adding an estimated $75.4K. The largest seller was Armistice Capital, exiting entirely with an estimated $1.16K sold.
- 11 institutional investors held ABVC BioPharma (ABVC) as of Q3 2022, up from 5 in Q2 2022.
- Funds reported $571K of ABVC BioPharma stock for Q3 2022, up 15% quarter-over-quarter.
- 7 funds opened new ABVC BioPharma positions in Q3 2022 and 1 closed out, a net change of +6 holders.
- The largest ABVC BioPharma buyer in Q3 2022 was Geode Capital Management, an estimated $75.4K added.
- The largest ABVC BioPharma seller in Q3 2022 was Armistice Capital, an estimated $1.16K sold.
Based on aggregated 13F filings for Q3 2022.